These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 28627393)

  • 1. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
    Yang HC; Chen PJ
    Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
    Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
    Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
    Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
    Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
    Yang YC; Yang HC
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
    Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
    World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
    Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
    J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
    Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
    mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 System with Dual gRNAs Synergically Inhibit Hepatitis B Virus Replication.
    Fei L; Sun S; Yang Q; Huang Y; Li Q; Tao S; Chen L
    Discov Med; 2024 Jun; 36(185):1169-1179. PubMed ID: 38926103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
    Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
    Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
    Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
    Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered extracellular vesicles for delivering functional Cas9/gRNA to eliminate hepatitis B virus cccDNA and integration.
    Zeng W; Zheng L; Li Y; Yang J; Mao T; Zhang J; Liu Y; Ning J; Zhang T; Huang H; Chen X; Lu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2284286. PubMed ID: 37982370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
    Peng C; Lu M; Yang D
    Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
    Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
    Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.
    Ramanan V; Shlomai A; Cox DB; Schwartz RE; Michailidis E; Bhatta A; Scott DA; Zhang F; Rice CM; Bhatia SN
    Sci Rep; 2015 Jun; 5():10833. PubMed ID: 26035283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.
    Seeger C; Sohn JA
    Mol Ther; 2016 Aug; 24(7):1258-66. PubMed ID: 27203444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
    Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
    Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Hepatitis B Virus DNA Using Designer Gene Editors.
    Zhang H; Tu T
    Clin Liver Dis; 2023 Nov; 27(4):895-916. PubMed ID: 37778776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of CRISPR/Cas9 Technology to HBV.
    Lin G; Zhang K; Li J
    Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas based antiviral strategies against HIV-1.
    Wang G; Zhao N; Berkhout B; Das AT
    Virus Res; 2018 Jan; 244():321-332. PubMed ID: 28760348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
    Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
    Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.